Temenos Welcomes Industry Leaders and Rising Stars of Fintech to Make Banking Better, Together at TCF Online 2021
12.5.2021 09:30:00 EEST | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that 10,000 business leaders and technologists will come together on 26 - 27 May at TCF Online 2021, the flagship event in banking. The two-day interactive, online-only event will feature keynotes from PayPal, Barclays and Varo, plus over 50 live and on-demand sessions and 50 industry speakers inspired by a shared mission to make banking better, together. Register for this free to attend event.
Powered by new technologies such as Cloud, AI and SaaS, banks of all sizes can deliver customer experiences that are better, faster and smarter. They can also achieve hyper-efficient cost models to deliver more value to their customers and leverage open ecosystems to enhance and extend their offering. At TCF Online 2021, Temenos will unveil game-changing innovations enabling banks to simplify their operations, innovate and collaborate at speed and digitally transform faster than ever before.
At TCF Online 2021, attendees from over 150 countries will also hear from some of the most influential industry experts in the financial sector, including:
- Ryan Prichard, VP, CTO of Global Credit, PayPal, on the latest innovations in payments, including how PayPal is disrupting the market with its new buy now, pay later product enabled by Temenos technology.
- Ashok Vaswani, CEO of Consumer Banking and Payments, Barclays, on the importance of banks being purpose-led and playing a greater role in the economy and society in a post-pandemic world.
- Colin Walsh, Founder and CEO, Varo, a year on after making history as the first fintech in the U.S. to obtain a national banking license, on making banking more accessible and inclusive for all.
- Jim Marous, co-publisher of The Financial Brand and top 100 influencer, on how banks can humanize their customer experience in a digital world and joining him on the virtual stage, Chris Parker, Co-CEO of Partners Federal Credit Union.
- Eric Purdum, General Manager, DXC on its collaboration with Temenos and accelerating the digital transformation for large tier-1 banks.
- David Hornery, Co-CEO and Co-Founder, Judo, on the future for challenger banks and Judo’s unique approach to the SME market in Australia.
- Barri Maggott, CEO, Curo Fund Services, on the digital transformation journey in funds administration.
- And Max Chuard, CEO of Temenos, on the once-in-a-generation opportunity digital presents for banking, unveiling Temenos’ latest innovations in cloud and AI that will propel the industry forward.
Max Chuard, CEO, Temenos, said: “The urgency for change in banking has never been greater. Consumers and business customers demand and expect fast, frictionless, personalized experiences. Covid-19 has accelerated the trend towards digital banking and new technologies such as Cloud, AI and SaaS make the business case for transformation compelling. Yet while challengers are innovating and launching rapidly on modern technology stacks, legacy systems are still holding banks back. Temenos technology gives all banks the freedom, agility and speed to innovate and adapt to changing customer behavior, business and regulatory change. At TCF Online 2021, our community of thousands will hear about the latest innovations and how together we will make banking better.”
TCF Online brings the key announcements, customer insights and latest software demonstrations from Temenos. To register for this free-to-attend event, visit www.temenos.com/events/tcf-online-2021.
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005935/en/
Contact information
Media Contacts
Jessica Wolfe & Scott Rowe
Temenos Global Public Relations
Tel: +1 610 232 2793 & +44 20 7423 3857
Email : press@temenos.com
Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: allnewgatetemenos@newgatecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom